oral semaglutide nejm soul trial cardiovascular outcomes 2024 results Reduces Events in People with Type 2 Oral Semaglutide and Cardiovascular Outcomes

Researchers who have struggled with tirzepatide losing effectiveness over time might consider whether switching to CagriSema when it becomes available could reignite weight loss through the different amylin-based mechanism

7 1 0 With evidence-backed treatments that improve cellular energy and balance the immune system, fatigue can stop feeling like something you have to push through

Tirzepatide is a dual-action agonist that activates both GIP and GLP-1 receptors simultaneously, delivering superior appetite control and metabolic effects, with trials showing up to 20%+ body weight reduction (SURMOUNT-1)

Due to delayed gastric emptying, patients using oral contraceptives should use non-oral or backup contraception for 4 weeks after initiation and each dose escalation